ArticlePituitary2015
Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab.
Article in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- A novel approach to hypophysitis: outcomes using non-glucocorticoid immunosuppressive therapy.European journal of endocrinology · 2023Review
- Clinical presentation and magnetic resonance imaging characteristics of lymphocytic hypophysitis: a systematic review with meta-analysis.Archives of medical science : AMS · 2023Review
- Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Recurrent autoimmune hypophysitis treated with rituximab: a case report.Journal of medical case reports · 2021Article
- Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.Ophthalmology and therapy · 2021Review
- Commentary: Rituximab in scleritis.Indian journal of ophthalmology · 2020Article
- Granulomatous hypophysitis causing compression of the internal carotid arteries reversible with azathioprine and rituximab treatment.Pituitary · 2020Review
- Infiltrative lymphocytic hypophysitis successfully treated with rituximab and mycophenolate mofetil.Endocrinology, diabetes & metabolism case reports · 2020Article
- A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease-A Case Report.Frontiers in endocrinology · 2020Article
- Autoimmune Hypophysitis With Systemic Lupus Erythematosus: A Case Report and Literature Review.Frontiers in endocrinology · 2020Review
- A 42-Year-Old Male with Diabetes Insipidus.Brain pathology (Zurich, Switzerland) · 2017Article
- Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects.Pituitary · 2016Review
- Involvement of B cells in non-infectious uveitis.Clinical & translational immunology · 2016Review
- Hypophysitis: Evaluation and Management.Clinical diabetes and endocrinology · 2016Review
- Bilateral Optic Neuritis and Hypophysitis With Diabetes Insipidus 1 Month After COVID-19 mRNA Vaccine: Case Report and Literature Review.Journal of investigative medicine high impact case reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutoimmune lymphocytic hypophysitis associates predominantly with other autoimmune endocrinopathies and is most commonly treated with glucocorticoids and/or decompressive pituitary surgery. Here we report a new association and treatment modality for lymphocytic hypophysitis.
methodsA 52-year-old woman presented with scleritis, uveitis, facial palsy, and central diabetes insipidus, accompanied by thickened pituitary stalk and enlarged pituitary on cranial MRI. Neurosarcoidosis was suspected and treatment with glucocorticoids and methotrexate initiated. Since symptoms persisted, infliximab (a monoclonal antibody that antagonizes tumor necrosis factor alpha) was added to her regimen. The patient initially improved but after 6 months developed recurrent pituitary enlargement, bilateral optic neuritis, and panhypopituitarism. To ascertain the nature of the pituitary lesion, she underwent transsphenoidal biopsy, which revealed lymphocytic hypophysitis with numerous CD20 positive B lymphocytes. The pathological finding suggested to us that administration of rituximab (a monoclonal antibody that lyzes B cells expressing CD20) could be useful. Following two courses of rituximab, the pituitary mass resolved and the corticotroph axis partially recovered. The patient has remained in remission during 3 years of follow up.
conclusionThis is the first report of hypophysitis occurring with the triad of scleritis, uveitis, and optic neuritis, as well as the first immunotherapy based on the sequential use of infliximab and rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.